Tell a Colleague About This Site

If you have a colleague that may be interested in learning about ENEST (Evaluating Nilotinib Efficacy and Safety in Clinical Trials) and Nilotinib, you may send him or her a customized letter with drug and clinical study details.

To send a letter to a colleague, fill in the following form and click "Send Letter".
If you wish, you may view the letter first by clicking "View Letter" below.

*Asterisk designates required field.

From:

Title:
Full Name:
*E-mail:

To:

Title:
Full Name:
*E-mail:

Please note that no information entered in this form is being stored, recorded or kept in any way.



Disclaimer: This is intended for healthcare professionals. This is an international website for the ENEST (Evaluating Nilotinib Efficacy and Safety in Clinical Trials) program. The information on this site is not country-specific and may contain ENEST program information that is different from where you practice. Please contact your local Novartis representative for the latest ENEST information specific to your country. The compound NILOTINIB described in this site has been approved in a number of countries for Ph+ CML; it has not been approved in any countries for KIT+ GIST. If NILOTINIB has not yet been approved in your country, there is no guarantee that NILOTINIB will become commercially available.